-
1 Comment
Chongqing Zhifei Biological Products Co., Ltd is currently in a long term uptrend where the price is trading 7.4% above its 200 day moving average.
From a valuation standpoint, the stock is 116.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 20.8.
Chongqing Zhifei Biological Products Co., Ltd's total revenue rose by 38.9% to $4B since the same quarter in the previous year.
Its net income has increased by 61.4% to $974M since the same quarter in the previous year.
Finally, its free cash flow grew by 176.8% to $2B since the same quarter in the previous year.
Based on the above factors, Chongqing Zhifei Biological Products Co., Ltd gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100000V20 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 46B |
|---|---|
| PE Ratio | 175.73 |
| Target Price | 35.2333 |
| Dividend Yield | 5.2% |
| Beta | 1.29 |
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, marketing, distribution, import, and export of vaccines and biological products in China. It also provides cold storage services. The company was founded in 2002 and is based in Chongqing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300122.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
